↓ Skip to main content

Systemic treatment with CAR-engineered T cells against PSCA delays subcutaneous tumor growth and prolongs survival of mice

Overview of attention for article published in BMC Cancer, January 2014
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (82nd percentile)

Mentioned by

twitter
2 tweeters
patent
2 patents

Citations

dimensions_citation
48 Dimensions

Readers on

mendeley
90 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Systemic treatment with CAR-engineered T cells against PSCA delays subcutaneous tumor growth and prolongs survival of mice
Published in
BMC Cancer, January 2014
DOI 10.1186/1471-2407-14-30
Pubmed ID
Authors

Victoria Hillerdal, Mohanraj Ramachandran, Justyna Leja, Magnus Essand

Abstract

Adoptive transfer of T cells genetically engineered with a chimeric antigen receptor (CAR) has successfully been used to treat both chronic and acute lymphocytic leukemia as well as other hematological cancers. Experimental therapy with CAR-engineered T cells has also shown promising results on solid tumors. The prostate stem cell antigen (PSCA) is a protein expressed on the surface of prostate epithelial cells as well as in primary and metastatic prostate cancer cells and therefore a promising target for immunotherapy of prostate cancer.

Twitter Demographics

The data shown below were collected from the profiles of 2 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 90 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 3 3%
Switzerland 1 1%
Portugal 1 1%
United Kingdom 1 1%
Australia 1 1%
Unknown 83 92%

Demographic breakdown

Readers by professional status Count As %
Researcher 19 21%
Student > Ph. D. Student 14 16%
Student > Master 13 14%
Student > Bachelor 11 12%
Student > Doctoral Student 7 8%
Other 9 10%
Unknown 17 19%
Readers by discipline Count As %
Agricultural and Biological Sciences 23 26%
Medicine and Dentistry 17 19%
Immunology and Microbiology 12 13%
Biochemistry, Genetics and Molecular Biology 7 8%
Pharmacology, Toxicology and Pharmaceutical Science 4 4%
Other 7 8%
Unknown 20 22%

Attention Score in Context

This research output has an Altmetric Attention Score of 7. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 28 December 2020.
All research outputs
#3,918,527
of 21,706,064 outputs
Outputs from BMC Cancer
#933
of 7,871 outputs
Outputs of similar age
#48,211
of 290,867 outputs
Outputs of similar age from BMC Cancer
#1
of 1 outputs
Altmetric has tracked 21,706,064 research outputs across all sources so far. Compared to these this one has done well and is in the 80th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 7,871 research outputs from this source. They receive a mean Attention Score of 4.3. This one has done well, scoring higher than 87% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 290,867 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 82% of its contemporaries.
We're also able to compare this research output to 1 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them